Investigation of possible aqueous phase formation during vaporization of sevoflurane

Background and Aims: Ultane®(sevoflurane; AbbVie Inc., North Chicago, IL, USA) has a dissolved water content of approximately 0.035% weight/weight (w/w). A previous report described formation of an aqueous layer in 4 of 13 sevoflurane vaporizers used in operating rooms. We investigated the condition...

Full description

Saved in:
Bibliographic Details
Main Authors: Shane Varughese (Author), Vikram G Kalthod (Author), James P Petzel (Author), Hans Peter Bacher (Author), Arthur W Wallace (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ffa1c744f0be4b74af9a44e55c033b02
042 |a dc 
100 1 0 |a Shane Varughese  |e author 
700 1 0 |a Vikram G Kalthod  |e author 
700 1 0 |a James P Petzel  |e author 
700 1 0 |a Hans Peter Bacher  |e author 
700 1 0 |a Arthur W Wallace  |e author 
245 0 0 |a Investigation of possible aqueous phase formation during vaporization of sevoflurane 
260 |b Wolters Kluwer Medknow Publications,   |c 2019-01-01T00:00:00Z. 
500 |a 0970-9185 
500 |a 10.4103/joacp.JOACP_53_18 
520 |a Background and Aims: Ultane®(sevoflurane; AbbVie Inc., North Chicago, IL, USA) has a dissolved water content of approximately 0.035% weight/weight (w/w). A previous report described formation of an aqueous layer in 4 of 13 sevoflurane vaporizers used in operating rooms. We investigated the conditions under which an aqueous layer could develop during vaporization of sevoflurane-water mixtures. Material and Methods: A temperature-controlled glass reactor was used to simulate a vaporizer. In four experiments, the vaporization of different sevoflurane-water mixtures was monitored over approximately 3-4 days. Samples were removed at regular intervals for analysis of water content. For confirmation, one experiment was replicated in a Tec 7 vaporizer. Results: Saturation of sevoflurane with water occurred at 0.11%-0.13% w/w at an ambient temperature; at greater water concentrations a separate aqueous phase was initially present. The sevoflurane-water azeotrope contained approximately 1.2% w/w water at 25°C. When the initial water content was <1.2% w/w (0.11%-1.03% w/w), vaporization resulted in a single phase of drier sevoflurane (final water concentration 0.02%-0.08% w/w). When the starting water concentration exceeded the azeotropic concentration (5.0% w/w), vaporization increased the water content, reaching 13% w/w at 71 h. Results under the low initial water condition were similar in the Tec 7 vaporizer. Conclusions: An increase in water concentration following vaporization of sevoflurane can only occur when the starting water content is higher than the azeotropic concentration and therefore cannot originate from the dissolved water present in the marketed product because the water concentration in Ultane®is 34 times lower than the azeotropic concentration. 
546 |a EN 
690 |a Anesthesia 
690 |a sevoflurane 
690 |a water 
690 |a Anesthesiology 
690 |a RD78.3-87.3 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Journal of Anaesthesiology Clinical Pharmacology, Vol 35, Iss 1, Pp 76-80 (2019) 
787 0 |n http://www.joacp.org/article.asp?issn=0970-9185;year=2019;volume=35;issue=1;spage=76;epage=80;aulast=Varughese 
787 0 |n https://doaj.org/toc/0970-9185 
856 4 1 |u https://doaj.org/article/ffa1c744f0be4b74af9a44e55c033b02  |z Connect to this object online.